Premium
Alpha‐internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy
Author(s) -
Mokhtari Karima,
Ducray François,
Kros Johan M.,
Gorlia Thierry,
Idbaih Ahmed,
Taphoorn Martin,
Wesseling Pieter,
HoangXuan Khe,
Van den Bent Martin,
Sanson Marc
Publication year - 2011
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.25827
Subject(s) - lomustine , oligodendroglial tumor , medicine , oncology , idh1 , procarbazine , isocitrate dehydrogenase , temozolomide , chemotherapy , vincristine , glioma , cancer research , oligodendroglioma , mutation , astrocytoma , biology , gene , cyclophosphamide , biochemistry , enzyme
Abstract BACKGROUND: Although it has been demonstrated that the neuronal intermediate filament alpha‐internexin (INA) is closely related to 1p19q codeletion in gliomas, its prognostic and predictive value has not yet been confirmed in a prospective trial. The authors of this report assessed the prognostic significance of INA expression and its correlation with relevant clinical and molecular characteristics in the prospective, randomized European Organization for Research and Treatment of Cancer (EORTC) 26951 trial of adjuvant procarbazine, lomustine, and vincristine (PCV) in patients with anaplastic oligodendroglial tumors (AOTs). METHODS: INA immunohistochemistry expression in tumors from 92 patients who were included in the EORTC 26951 trial was analyzed independently by 2 observers and was correlated with relevant clinical characteristics, including progression‐free survival (PFS) and overall survival (OS), and with molecular features, including 1p/19q codeletion, isocitrate dehydrogenase 1 and 2 gene ( IDH1/IDH2 ) mutation, and O‐6 methylguanine‐DNA methyltransferase ( MGMT ) promoter methylation status. RESULTS: INA expression was observed in 33 tumors and was strongly correlated with 1p/19q codeletion, IDH1 mutations, and MGMT promoter methylation. It was associated with significantly better PFS and OS independent of the treatment received. By using Cox proportional hazard modeling for OS with stepwise selection, INA expression, patient age, and performance status were identified as independent prognostic factors. The results indicated that INA expression may have an impact on the efficacy of combined radiotherapy plus PCV. CONCLUSIONS: In a homogeneously treated group of patients with grade III AOTs, INA expression had strong favorable prognostic significance for OS and may have predictive value for sensitivity to chemotherapy. Cancer 2011. © 2011 American Cancer Society.